LICENSE AGREEMENTLicense Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research • California
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. TERMINATION AND LICENSE AGREEMENTTermination and License Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research • Indiana
THIS TERMINATION AND LICENSE AGREEMENT (“Agreement”), effective as of December 18, 2003 (“Effective Date”), is made by and among Eli Lilly and Company, a corporation organized under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana, 46285 (hereinafter “Lilly”), Pharmaceutical Product Development, Inc., a corporation organized under the laws of the State of North Carolina (hereinafter “PPD”), GenuPro, Inc., a wholly-owned subsidiary of PPD, and a corporation organized under the laws of North Carolina (hereinafter “GenuPro”) and APBI Holdings, LLC, a wholly-owned subsidiary of PPD, and a limited liability company organized under the laws of North Carolina (hereinafter “APBI Holdings”). (Each party to this Agreement is hereinafter referred to as a “Party”, or collectively, the “Parties.” All references to a Party shall be deemed to include that Party’s Affiliates).
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. Amendment No. 1 To LICENSE AGREEMENTLicense Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research
This Amendment No. 1 to License Agreement (“Amendment No. 1”) is effective as of the 26th day of December, 2003 (the “Amendment Effective Date”) by and among Pharmaceutical Product Development, Inc., a North Carolina corporation having a place of business at 3151 South Seventeenth Street, Wilmington, NC 28412 (hereinafter “PPD”) and its wholly owned subsidiary GenuPro, Inc., d/b/a PPD GenuPro, a North Carolina corporation having a place of business at 3900 Paramount Parkway, Morrisville, North Carolina 27560 (hereinafter “GenuPro”), and ALZA Corporation, a Delaware corporation having a place of business at 1900 Charleston Road, Mountain View, CA 94043 (hereinafter “Licensee”). PPD, GenuPro and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. COLLABORATION AGREEMENTCollaboration Agreement • February 26th, 2004 • Pharmaceutical Product Development Inc • Services-commercial physical & biological research • North Carolina
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into and made effective as of November 19, 2003 (the “Effective Date”) by and between SYRRX, INC., a Delaware corporation having its principal place of business at 10410 Science Center Drive, San Diego, CA 92121 (“Syrrx”), and DEVELOPMENT PARTNERS, LLC, a Delaware limited liability company having its principal place of business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD”), a wholly owned subsidiary of PHARMACEUTICAL PRODUCT DEVELOPMENT, INC., a North Carolina corporation having its principal place of business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD, Inc.”). Syrrx and PPD are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” PPD, Inc. is a party to this Agreement solely for purposes of Sections 17.18 and 17.19.
